Tyrosine kinase inhibitorFDA-approvedFirst-line
Dacomitinib
How it works
Blocks the epidermal growth factor receptor (EGFR) on cancer cells, preventing them from growing and dividing.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
Clinical trials have shown that dacomitinib can improve progression-free survival in patients with EGFR-mutated non-small cell lung cancer, with a median progression-free survival of approximately 14.7 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Dacomitinib Shows Promise for Lung Cancer Patients Resistant to Other Treatments | Lung Cancer | observational | The objective response rate was 33.3%, and the disease control rate was 78.6%. | Source → |
| Testing Treatments for EGFR-Mutated Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Low-Dose Dacomitinib Shows Promise for Lung Cancer Patients | Lung Cancer | observational | The objective response rate in the low-dose dacomitinib group was 67.7%. | Source → |
| Paronychia and Skin Rash in Lung Cancer Patient Treated with Dacomitinib | Lung Cancer | observational | — | Source → |
| Comparing Two Cancer Treatments for Lung Cancer Patients | Lung Cancer | observational | The partial response rates for first-line treatment with afatinib and dacomitinib were 85.7 and 80.6%, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.